Pure Global
NCT06096922

AI-based Frailty Assessment Tool for Patients Undergoing Cardiac Surgery

Frailty Assessment Tool for Patients Undergoing Cardiac Surgery Based on Artificial Intelligence Multimodal Non-contact Monitoring.
China National Center for Cardiovascular Diseases·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Frailty
Drug/Device/Intervention
No intervention
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
China National Center for Cardiovascular Diseases
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Dec 01, 2024
Enrollment
500 participants
Primary outcome

One-dimensional matrix vector composed of five frailty scale results

Summary

The main purpose of this study is to establish a frailty automatic evaluation index AI
 frailty index based on artificial intelligence multi-modal non-contact monitoring
 information analysis. At the same time, the study will explore the correlation between ' AI
 weakness index ' and perioperative and long-term prognosis and quality of life.

ICD-10 classifications
Unattended deathIndividuals with autosomal fragile site
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06096922
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06096922 through Pure Global AI's free database. This phase not specified trial is sponsored by China National Center for Cardiovascular Diseases and is currently Recruiting. The study focuses on Frailty. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.